News | ESC | September 12, 2017

New FOURIER Analysis Examines How Low Cholesterol Can Safely Go

New FOURIER Analysis Examines How Low Cholesterol Can Safely Go

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively fewer cardiovascular events and appears to pose no safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the FOURIER Trial. The results were presented at the 2017 European Society of Cardiology (ESC) Congress and published in the Lancet.

“The findings suggest that a lower LDL-C target - far below current guidelines - can safely be considered to further reduce the risk of recurrent cardiovascular events in high risk patients,” said investigator Robert Giugliano, M.D., SM, from Brigham and Women’s Hospital and Harvard Medical School, in Boston.
 
“These findings are unique in that they represent the first analysis of a large cohort of patients to achieve such very low LDL-C levels, namely being less than one-third of the most common treatment goal of below 1.8 millimoles per liter (mmol/L) for highest risk patients,” he said.
 
The FOURIER Trial randomized patients with stable atherosclerotic cardiovascular disease and treated with background statin therapy, to either placebo or evolocumab – a proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody.

Initial results from the trial showed that evolocumab lowered LDL-C levels to a median of 0.8 mmol/L and significantly reduced the risk of cardiovascular events at a median follow-up of 2.2 years.
 
The new analysis examined efficacy and safety endpoints according to degree of LDL-C reduction at one month. In addition,  a study known as EBBINGHAUS embedded within the larger analysis explored effects on cognition using a validated tablet-based tool.

A total of 25,982 patients with an LDL-C assessment at week four who did not experience a primary efficacy or pre-specified safety event prior to the week 4 visit were included in the analysis.

The study showed that the risk of the primary efficacy endpoint — a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina declined steadily as LDL-C levels decreased, with no significant association between LDL-C level and adverse events.

A similar reduction was observed in the key secondary endpoint, with 2,669 subjects in the lowest LDL-C category (<0.5 mmol/L) at 4 weeks experiencing the lowest rate for cardiovascular death, or myocardial infarction (adjusted hazard ratio 0.69, 95% CI 0.56-0.85, P=0.0001) compared to the group with highest LDL-C (> 2.6 mmol/L).
 
Exploratory analyses in a subgroup of 504 patients with an LDL-C <0.25 mmol/L showed even further reduction in cardiovascular events with no increase in safety events.

Additionally, among 1,154 patients who underwent formal cognitive testing prior to, or on the first day of study treatment as part of the EBBINGHAUS study, there were no adverse effects on memory, executive function, memory, or reaction time associated with lower LDL-C.

“Although longer-term follow-up will be important, the totality of evidence to date from trials of intensive lipid lowering supports reduction of LDL-C in high-risk patients to levels below those currently recommended in cholesterol guidelines,” Giugliano said.

The study was sponsored by Amgen. 

Giugliano reports grants and personal fees from Amgen during the conduct of the study, as well as grants and other support from Amgen and personal fees from Amarin, American College of Cardiology, AngelMed, Beckman-Coulter, Boehringer-Ingelheim, Bristol-Myers-Squibb, CVS Caremark, GlaxoSmithKline, Janssen, Lexicon, Portola, Pfizer, Regeneron, Sanofi-Aventis, St. Jude Medical, and Stealth Peptides outside the submitted work.

For more information: http://congress365.escardio.org

 

Links to all the late-breaking ESC 2017 trial presentations.

 

Reference:

1. Robert Giugliano, Terje Pedersen, Jeong-Gun Park, et al. “Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.” Lancet, Published: 28 August 2017. DOI: http://dx.doi.org/10.1016/S0140-6736(17)32290-0.


Related Content

Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home June 12, 2024
Home
News | Cardiovascular Clinical Studies

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
News | Cardiovascular Clinical Studies

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization ...

Home May 31, 2024
Home
News | Cardiovascular Clinical Studies

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

Home May 29, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
Subscribe Now